viewAusCann Group Holdings Ltd

AusCann Group pilot study reveals unique capsule for cannabinoid medicines

The study has developed a new hard capsule to deliver its cannabinoid medicines.

cannabis leaf near green pills and stethoscope
The new hard capsule form will be a game changer for doctors and patients

AusCann Group Holdings Ltd (ASX:AC8) has completed a successful pilot study of its final dose form for its proprietary cannabinoid medicines.

Through its research, AusCann has developed a unique effective stable oral dose form which provides consistent and stable dosages of the active cannabinoids.

The study was carried out over the past ten months to be ready for the release of AusCann’s first cannabinoid medicines in first half of 2019.

READ: Auscann Group raises more capital, well-funded for manufacturing cannabinoid medicines in Australia

AusCann’s managing director Elaine Darby said: “AusCann has developed something truly unique in the world of cannabinoid medicines.

“Delivery of consistent and stable products has been an issue that plagues the cannabis medicine industry.

“This new hard capsule will be a game changer for doctors and patients as it is easy to use and will give consistent treatment outcomes every time.

“We are thrilled with the success of this study and look forward to releasing these new pharmaceuticals next year.”

Well-funded to deliver on strategy

Following a placement and subsequent share purchase plan last month, AusCann is well-funded to deliver on its path of developing safe, efficacious, clinically-validated and cost-effective cannabinoid medicines.

Patent lodged for unique capsule dose

Currently, medicinal cannabis is typically administered via oral liquids, liquid sprays, hard or soft-shell gelatin capsules containing cannabinoids dissolved in oils, or inhalation of dried material or extracts.

The main drawback to these formulations is the stability of the active cannabinoids which results in variability in the composition and the efficacy of the formulations.

Quick facts: AusCann Group Holdings Ltd


Price: 0.092 AUD

Market Cap: $40.53 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


Auscann targeting pain management with Australian cannabinoid products

Elaine Darby, managing director of Auscann Group Holdings Ltd (ASX:AC8), spoke to Proactive Investors at the ASX Small and Mid-Cap Conference in Sydney. Auscann is continuing to make steady progress towards releasing its first medicinal cannabis products during the financial year 2019....

on 6/9/18

2 min read